Peptide contraception by inhibition of ovulation with intranasal GnRH superagonist: clinical and metabolic aspects.
D000281:Administration, Intranasal; D001842:Bone and Bones / Q000378:metabolism; D003271:Contraceptive Agents, Female; D004717:Endometrium / Q000033:anatomy & histology / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D017274:Nafarelin; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000097:blood
D003271:Contraceptive Agents, Female; D008055:Lipids; D008074:Lipoproteins; D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol